Most Read Articles
Dr. Wong Soon Tee, 28 May 2020
Acne is a common skin problem seen in primary care. Dr Wong Soon Tee of Assurance Skin Clinic at Mt Elizabeth Novena Hospital, Singapore shares his insights with Pearl Toh on how to manage acne in the primary care setting.
11 Aug 2020
During the Allergic Rhinitis (AR) Boot Camp held in conjunction with the Bayer Pharmacist Congress 2020, Professor Dr Baharudin Abdullah discussed the management of AR in the primary care setting and the importance of using patient profiles to guide the choice of antihistamines.
Rachel Soon, 28 Aug 2020
MOH Director-General Tan Sri Dato' Seri Dr Noor Hisham Abdullah speaks about NHMS 2019 and pharmacists' roles in combating NCDs among Malaysians.
Audrey Abella, 07 Sep 2020
Mavacamten, a first-in-class myosin inhibitor, may be the first targeted therapy to address the underlying cause of obstructive hypertrophic cardiomyopathy (OHCM), the EXPLORER-HCM trial has shown.

Ferric carboxymaltose corrects anaemia in peritoneal dialysis patients

14 Jan 2020

Treatment with intravenous (IV) ferric carboxymaltose (FCM) safely and effectively treats iron-deficiency anaemia in patients undergoing peritoneal dialysis (PD), as shown in a recent study.

The safety analysis included 91 PD patients (mean age, 57.7 years) who initiated FCM treatment, while the efficacy analysis involved 70 patients (mean age, 50.9 years). All patients had available follow-up data of up to 12 months.

There was no hypersensitivity reaction documented, nor were there instances of FCM discontinuation or dose adjustment due to a serious adverse event (SAE). The most common non-SAEs were headache (four events), mild hypotension (three events) and hypertension (two events), among others.

In terms of efficacy, a large portion of patients achieved ferritin levels of 200–800 ng/mL (68.6 percent), transferrin saturation (TSAT) >20 percent (78.4 percent), and TSAT >20 percent and ferritin >200 ng/mL (62.8 percent) after 12 months of FCM initiation (p<0.01). Haemoglobin (Hb) levels remained at >11 g/dL with a lower dose of darbepoetin throughout the follow-up.

A subgroup analysis of patients naïve to IV iron and with absolute vs relative iron deficiency (n=51) revealed that 76.5 percent had ferritin levels >200 ng/mL, 80.4 percent had TSAT >20 percent, and Hb levels increased (1.2 g/dL) following 4 months of FCM treatment (p<0.01).

Although prospective studies are warranted, the present data indicate that “a high-dose and low-frequency strategy with FCM concurrent with routine hospital visits could be easily adapted to home PD,” researchers said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Dr. Wong Soon Tee, 28 May 2020
Acne is a common skin problem seen in primary care. Dr Wong Soon Tee of Assurance Skin Clinic at Mt Elizabeth Novena Hospital, Singapore shares his insights with Pearl Toh on how to manage acne in the primary care setting.
11 Aug 2020
During the Allergic Rhinitis (AR) Boot Camp held in conjunction with the Bayer Pharmacist Congress 2020, Professor Dr Baharudin Abdullah discussed the management of AR in the primary care setting and the importance of using patient profiles to guide the choice of antihistamines.
Rachel Soon, 28 Aug 2020
MOH Director-General Tan Sri Dato' Seri Dr Noor Hisham Abdullah speaks about NHMS 2019 and pharmacists' roles in combating NCDs among Malaysians.
Audrey Abella, 07 Sep 2020
Mavacamten, a first-in-class myosin inhibitor, may be the first targeted therapy to address the underlying cause of obstructive hypertrophic cardiomyopathy (OHCM), the EXPLORER-HCM trial has shown.